Skip to the content
  • Our Company
    • Management Team
    • Board Members
    • Events
  • Our Approach
  • Partner
  • Careers
  • Resources
  • News
Menu
  • Our Company
    • Management Team
    • Board Members
    • Events
  • Our Approach
  • Partner
  • Careers
  • Resources
  • News
  • Contact
Menu
  • Contact

Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.

read more
Path 3
  • Scientific Publication
  • June 24, 2020

Geiger M, et al. (2020) “Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.” Nat Commun. 11: 3196. doi: 10.1038/s41467-020-16838-w

Abstract

T-cell bispecific antibodies (TCBs) crosslink tumor and T-cells to induce tumor cell killing. While TCBs are very potent, on-target off-tumor toxicity remains a challenge when selecting targets. Here, we describe a protease-activated anti-folate receptor 1 TCB (Prot-FOLR1-TCB) equipped with an anti-idiotypic anti-CD3 mask connected to the anti-CD3 Fab through a tumor protease-cleavable linker. The potency of this Prot- FOLR1-TCB is recovered following protease-cleavage of the linker releasing the anti-idiotypic anti-CD3 scFv. In vivo, the Prot-FOLR1-TCB mediates antitumor efficacy comparable to the parental FOLR1-TCB whereas a noncleavable control Prot-FOLR1-TCB is inactive. In contrast, killing of bronchial epithelial and renal cortical cells with low FOLR1 expression is prevented compared to the parental FOLR1-TCB. The findings are confirmed for mesothelin as alternative tumor antigen. Thus, masking the anti-CD3 Fab fragment with an anti-idiotypic mask and cleavage of the mask by tumor-specific proteases can be applied to enhance specificity and safety of TCBs.

PreviousNimble Announces Collaboration to Discover and Develop Novel Peptide-Based Compounds for SARS-CoV-2 Diagnostics
NextNimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics
PreviousNimble Announces Collaboration to Discover and Develop Novel Peptide-Based Compounds for SARS-CoV-2 Diagnostics
NextNimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact

603 Science Dr
Madison, WI, USA 53711

LinkedIn
  • Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech
    Read More